Ahmed El-Modir retweeted
🚨 55.6% response rate in heavily pretreated ovarian cancer!
Could Rinatabart sesutecan (Rina-S) be the next major ADC in gynecologic oncology?
📌 RAINFOL-01 | Phase 1/2 | IJGC 2026
An FRα-directed ADC carrying an exatecan payload, evaluated without FRα-based patient selection.
🔹 Ovarian cancer (120 mg/m²)
• ORR: 55.6%, including 4 complete responses
• Median DoR: Not reached
🔹 Endometrial cancer
• ORR: 50% (100 mg/m²)
• ORR: 44.1% (120 mg/m²)
• Median DoR: 9.8–13.5 months
⚠️ Significant grade ≥3 cytopenias, particularly neutropenia and anemia.
💡 My take: Promising activity across FRα expression levels, but small, noncomparative cohorts. Phase 3 confirmation is essential.
@oncoalert #OvarianCancer #EndometrialCancer #ADC
Full paper link in comment below ⬇️
Ahmed El-Modir retweeted
NIAGARA Trial Explores Urinary Tumor DNA as a Biomarker in Bladder Cancer.
Urinary tumor DNA in #MIBC from NIAGARA. @MichvdHeijden @NKI_nl joins @ERPlimackMD @FoxChaseCancer to discuss utDNA and ctDNA with perioperative durvalumab. pCR was 72% if utDNA-negative vs 18% if positive. #WatchNow on UroToday > bit.ly/4eCoewi
Ahmed El-Modir retweeted
Cardiovascular Risk Assessment and Management in #ProstateCancer Survivorship.
Cardiovascular care is #ProstateCancer survivorship care. @ravi_b_parikh @WinshipAtEmory notes only 68% of VA patients received comprehensive CV risk assessment and outlines a structured approach starting at the ADT conversation. @PCFnews #WatchNow on UroToday > bit.ly/3VJjGhh
Ahmed El-Modir retweeted
ADT Class and Cardiovascular Risk: A Large Retrospective Analysis in Prostate Cancer.
Does ADT class affect cardiovascular risk in #ProstateCancer? @OncHahn @UTMDAnderson joins @neerajaiims @DanaFarber to discuss a large real-world analysis of major adverse cardiac events in men receiving androgen deprivation therapy. #WatchNow on UroToday > bit.ly/4ykeNIZ
Ahmed El-Modir retweeted
#ProstateCancer Highlights and Clinical Implications. @CaPsurvivorship, @DanaFarber, and @zklaassen_md review the DASL-HiCaP, PROTEUS, CAPItello-281, and JNJ-6143 studies from #ESMO26 in this conversation on UroToday > bit.ly/4iwbatD
Ahmed El-Modir retweeted
Optimizing Therapy for Locally Advanced #ProstateCancer. Presented by @BarbaraJereczek. #ESMO26 written coverage by @zklaassen_md > bit.ly/4z7fiav #RadOnc #GUOnc @myESMO
Ahmed El-Modir retweeted
Management of #mCRPC: Personalized Treatment Selection and Sequencing. Presented by Dr. Deborah Mukherji, MBBS, FRCP. #ESMO26 written coverage by @zklaassen_md > bit.ly/4eSjvGU #ProstateCancer #PrecisionOncology @myESMO
Ahmed El-Modir retweeted
LuCAB: Phase I/II Trial of Cabazitaxel + 177Lu-PSMA in mCRPC. Presented by @LouiseKostos @PeterMacCC. #ESMO26 written coverage by @rksayyid > bit.ly/4zULptV #ProstateCancer #mCRPC #ClinicalTrials @myESMO
Original Article: Divarasib as Compared with Sotorasib or Adagrasib in 𝘒𝘙𝘈𝘚 G12C–Mutated NSCLC (phase 3 Krascendo 1 trial) nej.md/4BiCvbk
#ESMO26 | @myESMO
Ahmed El-Modir retweeted
🚨 PD-L1 ≥50% NSCLC: Is pembrolizumab alone enough?
🔥 PERSEE Phase III | #ESMO26
Pembrolizumab + chemotherapy vs pembrolizumab alone:
📊 PFS: 16.1 vs 6.9 months (HR 0.56; p<0.001)
📊 OS: 50.2 vs 29.9 months (HR 0.77; CI crosses 1)
🎯 PFS benefit persisted even with PD-L1 ≥90%.
💡 Verdict: Strong PFS benefit, but OS advantage remains unproven.
@myesmo @ESMO_open @ASCO @oncoalert
Full paper link in comment below ⬇️
🚨 PD-L1 ≥50% in NSCLC: Is pembrolizumab alone enough?
🔥 PERSEE Phase III | #ESMO26
Concomitant publication in Annals of Oncology.
Pembrolizumab + chemotherapy vs pembrolizumab alone:
📊 PFS: 16.1 vs 6.9 months (HR 0.56)
🎯 ORR: 77.5% vs 50.3%
⚠️ Grade ≥3 toxicity: 54% vs 19%
OS: 50.2 vs 29.9 months (HR 0.77), not statistically significant.
💡 Verdict: Better disease control, but at a substantial toxicity cost. Is PD-L1 ≥50% alone sufficient to omit chemotherapy?
@ESMO_open @myesmo @ASCO @oncoalert
#ESMO26 #LungCancer
Original Article: Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC (phase 3 OptiTROP-Lung06 trial) nej.md/4Bo3liu
#ESMO26 | @myESMO
Original Article: Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer (phase 3 DeLLphi-305 trial) nej.md/4iveIgW
#ESMO26 | @myESMO
Ahmed El-Modir retweeted
ESMO 2026 | TOP 10 LUNG CANCER TRIALS TO WATCH!
From DLL3 bispecifics and next-generation KRAS inhibitors to novel ADCs, major lung cancer data are coming at #ESMO26.
🔥 My Top 10 Trials
1.DeLLphi-305 | Tarlatamab + durvalumab | ES-SCLC
2.SAFFRON | Osimertinib + savolitinib | MET-altered EGFR+ NSCLC
3.Krascendo 1 | Divarasib vs approved KRAS G12C inhibitors
4.OptiTROP-Lung06 | Sacituzumab tirumotecan + pembrolizumab | 1L NSCLC
5.OptiTROP-Lung04 | TROP2 ADC after EGFR-TKI progression
6.SigVie-002 | Integrin αvβ6 ADC vs docetaxel
7.SARON | Consolidation RT in oligometastatic NSCLC
8.PERSEE | Pembrolizumab ± chemotherapy | PD-L1 ≥50%
9.DeLLphi-304 | Long-term survival with tarlatamab
10.ASTRIDE | Serplulimab vs atezolizumab + chemotherapy | ES-SCLC
Three Presidential presentations deserve special attention: DeLLphi-305, SAFFRON and Krascendo 1.
Which trial could have the biggest impact on lung cancer treatment?
@myesmo @ESMO_open @ASCO @oncoalert
#ESMO26 #LungCancer #Oncology
🤖 Made with AI
🚨 ESMO 2026: 15 Trials That Could Change Oncology Practice!
From personalized cancer vaccines and bispecific antibodies to next-generation ADCs, major results are coming.
🔥 My Top 15 to Watch:
1. INTerpath-001 | Melanoma
2. SAFFRON | EGFR+ NSCLC
3. Krascendo 1 | KRAS G12C NSCLC
4. DeLLphi-305 | ES-SCLC
5. HARMONi-GI1 | Biliary
6. VOLGA | Bladder
7. DASL-HiCaP | Prostate
8. NATALEE | Breast
9. TRIO-US B-12 TALENT | Breast
10. ENERGIZE | Bladder
11. CLARITY-Gastric 01 | Gastric
12. KEYNOTE-C93 | Endometrial
13. KEYNOTE-B49 | Breast
14. LITESPARK-011 | RCC
15. SigVie-002 | NSCLC
📊 The big question: Which trials will deliver meaningful survival benefits and redefine standards of care?
Not every positive trial is practice-changing.
👨⚕️ Oncologists, which trial are you watching most closely?
#ESMO26 #Oncology #CancerResearch
@ASCO @oncoalert @myesmo @esmo_open
Presented at #ESMO26:
In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with tarlatamab–durvalumab maintenance therapy and 12.7 months with durvalumab alone. Full DeLLphi-305 trial results: nej.md/4iveIgW
@myESMO

ALT A graph from the Original Article "Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer." The trial name, DeLLphi-305, is in parentheses after the title. The graph shows the overall survival (intention-to-treat population). The trial results are being presented at the European Society For Medical Oncology 2026 Congress. The logo of the New England Journal of Medicine is at the bottom.
Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…
24
#bladdercancer
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…
35
Ahmed El-Modir retweeted
Denosumab vs Zoledronic Acid in Bone Metastases
• 3 pivotal phase III trials
• >5,700 patients in pooled analysis
• Modest reduction in skeletal-related events with denosumab (HR 0.83)
• No overall survival benefit
• More hypocalcemia with denosumab
• Less renal toxicity and no dose adjustment
Choose based on efficacy, renal function, convenience, cost, and patient preference.
#Oncology #MedTwitter #BoneMetastases #BreastCancer #ProstateCancer #MVOnco








































